Payment overview · 2025
General Payments
$121.69
5 reported records · 5 companies
Healthcare provider profile · identity verified
James Leon Jablonski, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SHILOH, IL · NPI 1194712513
Verified facts
What the public records show
CMS Open Payments records show James Leon Jablonski, M.D. received $121.69 in general payments during 2025 across 5 reported records.
INTUITIVE SURGICAL, INC. accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $53.19 | 43.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.78 | 16.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.19 | 14.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.73 | 13.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.80 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.69 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $53.19 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 125 |
| Lisinopril | Lisinopril | 438 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 61 |
| Losartan Potassium | Losartan Potassium | 239 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 55 |
| Omeprazole | Omeprazole | 160 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 47 |
| Metformin Hcl | Metformin Hcl | 145 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 51 |
| Simvastatin | Simvastatin | 142 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 33 |
| Furosemide | Furosemide | 129 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 35 |
| Allopurinol | Allopurinol | 123 | 39 |
| Ozempic | Semaglutide | 115 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 39 |
| Eliquis | Apixaban | 105 | 18 |
| Prednisone | Prednisone | 104 | 75 |
| Metformin Hcl Er | Metformin Hcl | 103 | 32 |
| Gabapentin | Gabapentin | 100 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 32 |
| Sertraline Hcl | Sertraline Hcl | 99 | 35 |
| Jardiance | Empagliflozin | 98 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 35 |
| Meloxicam | Meloxicam | 85 | 29 |
| Potassium Chloride | Potassium Chloride | 84 | 24 |
| Alendronate Sodium | Alendronate Sodium | 78 | 21 |
| Tramadol Hcl | Tramadol Hcl | 77 | 24 |
| Carvedilol | Carvedilol | 76 | 22 |
| Glipizide Er | Glipizide | 73 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 17 |
| Alprazolam | Alprazolam | 65 | 14 |
| Famotidine | Famotidine | 61 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 16 |
| Lorazepam | Lorazepam | 58 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 18 |
| Trazodone Hcl | Trazodone Hcl | 56 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 15 |
| Glimepiride | Glimepiride | 53 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Spironolactone | Spironolactone | 51 | 14 |
| Azithromycin | Azithromycin | 50 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 26 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Ketoconazole | Ketoconazole | 40 | 23 |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 15 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.69 · 5 records | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System, JARDIANCE, LEQVIO, OTEZLA, QULIPTA, REPATHA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error